{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:06:17Z","timestamp":1794265577060,"version":"4.9.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.vaccine.2009.04.071","type":"journal-article","created":{"date-parts":[[2009,5,29]],"date-time":"2009-05-29T13:20:28Z","timestamp":1243603228000},"page":"B3-B12","source":"Crossref","is-referenced-by-count":338,"special_numbering":"S2","title":["Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis"],"prefix":"10.1016","volume":"27","author":[{"given":"Johan","family":"Holst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepcion Campa","family":"Huergo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Oster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"O\u2019Hallahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Rosenqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vaccine.2009.04.071_bib1","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1017\/S0950268805005339","article-title":"The natural history of meningococcal carriage and disease","volume":"134","author":"Trotter","year":"2006","journal-title":"Epidemiol Infect"},{"issue":"2","key":"10.1016\/j.vaccine.2009.04.071_bib2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1128\/JCM.32.2.323-330.1994","article-title":"Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population","volume":"32","author":"Caugant","year":"1994","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2009.04.071_bib3","series-title":"Vaccines","first-page":"399","article-title":"Meningococcal vaccines","author":"Granoff","year":"2008"},{"key":"10.1016\/j.vaccine.2009.04.071_bib4","series-title":"WHO practical guidelines","article-title":"Control of epidemic meningococcal disease","author":"Anonymous","year":"1998"},{"issue":"2","key":"10.1016\/j.vaccine.2009.04.071_bib5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jama.2007.29-c","article-title":"Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial","volume":"299","author":"Snape","year":"2008","journal-title":"JAMA"},{"issue":"8346","key":"10.1016\/j.vaccine.2009.04.071_bib6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2009.04.071_bib7","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0264-410X(01)00299-7","article-title":"Planning, registration and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story","volume":"20","author":"Miller","year":"2001","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.vaccine.2009.04.071_bib8","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","article-title":"Meningococcal disease","volume":"344","author":"Rosenstein","year":"2001","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2009.04.071_bib9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.inf.0000202065.03366.0c","article-title":"Population-based analysis of meningococcal disease mortality in the United States: 1990\u20132002","volume":"25","author":"Sharip","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.vaccine.2009.04.071_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1574-6976.2006.00060.x","article-title":"A surveillance network for meningococcal disease in Europe","volume":"31","author":"Trotter","year":"2007","journal-title":"FEMS Microbiol Rev"},{"issue":"2","key":"10.1016\/j.vaccine.2009.04.071_bib11","first-page":"195","article-title":"Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba","volume":"14","author":"Sierra","year":"1991","journal-title":"NIPH Ann"},{"issue":"8775","key":"10.1016\/j.vaccine.2009.04.071_bib12","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of outer membrane vesicle vaccine against serogroup B meningococcal disease in Norway","volume":"338","author":"Bjune","year":"1991","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2009.04.071_bib13","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1086\/517385","article-title":"New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4","volume":"177","author":"Martin","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2009.04.071_bib14","doi-asserted-by":"crossref","unstructured":"Holst J, Aaberge IS, Oster P, Lennon D, Martin D, O\u2019Hallahan J, et al. A \u2018tailor made\u2019 vaccine trialled as part of public health response to group B meningococcal epidemic in New Zealand. Euro Surveill 2003; 7(30), http:\/\/www.eurosurveillance.org\/ViewArticle.aspx?.","DOI":"10.2807\/esw.07.30.02262-en"},{"issue":"16","key":"10.1016\/j.vaccine.2009.04.071_bib15","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","article-title":"Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines. A randomized controlled trial in Chile","volume":"281","author":"Tappero","year":"1999","journal-title":"JAMA"},{"issue":"17\u201318","key":"10.1016\/j.vaccine.2009.04.071_bib16","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.vaccine.2005.01.058","article-title":"The concept of \u201ctailor-made\u201d, protein-based, outer membrane vesicle vaccines against meningococcal disease","volume":"23","author":"Holst","year":"2005","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2009.04.071_bib17","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1128\/CVI.13.4.486-491.2006","article-title":"The VR2 epitope on the PorA P1.7-2 4 protein is the major target for the immune response elicited by the strain-specific Group B meningococcal vaccine MeNZB","volume":"13","author":"Martin","year":"2006","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2009.04.071_bib18","first-page":"69","article-title":"Serotype determinant protein of Neisseria meningitides. Large scale preparation by direct detergent treatment of the bacterial cells","volume":"89","author":"Helting","year":"1981","journal-title":"Acta Pathol Microbiol Scand [C]"},{"key":"10.1016\/j.vaccine.2009.04.071_bib19","series-title":"Bacterial vaccines","first-page":"58","article-title":"Polysaccharides and membrane vaccines","author":"Poolman","year":"1990"},{"key":"10.1016\/j.vaccine.2009.04.071_bib20","series-title":"Methods in molecular medicine, vol. 66. Meningococcal disease protocols","first-page":"81","article-title":"Preparation of outer membrane protein vaccines against meningococcal disease","author":"Frasch","year":"2001"},{"issue":"2","key":"10.1016\/j.vaccine.2009.04.071_bib21","first-page":"67","article-title":"Production, characterization and control of MenB-vaccine \u201cFolkehelsa\u201d: an outer membrane vesicle vaccine against group B meningococcal disease","volume":"14","author":"Holst Fredriksen","year":"1991","journal-title":"NIPH Ann"},{"issue":"2","key":"10.1016\/j.vaccine.2009.04.071_bib22","first-page":"147","article-title":"Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey","volume":"14","author":"H\u00f8iby","year":"1991","journal-title":"NIPH Ann"},{"key":"10.1016\/j.vaccine.2009.04.071_bib23","series-title":"Modulation of the immune response to vaccine antigens, vol. 92","first-page":"323","article-title":"Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidids outer membrane vesicle vaccine","author":"Rosenqvist","year":"1998"},{"issue":"3","key":"10.1016\/j.vaccine.2009.04.071_bib24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0092-1157(89)90017-6","article-title":"Measurement of lipopolysaccharide (endotoxin) in meningococcal protein and polysaccharide preparations for vaccine usage","volume":"17","author":"Tsai","year":"1989","journal-title":"J Biol Stand"},{"issue":"9","key":"10.1016\/j.vaccine.2009.04.071_bib25","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/prca.200700204","article-title":"Exploring the proteome of meningococcal outer membrane vesicle vaccines","volume":"1","author":"Wheeler","year":"2007","journal-title":"Proteomics Clin Appl"},{"issue":"6","key":"10.1016\/j.vaccine.2009.04.071_bib26","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/pmic.200500164","article-title":"Outer membrane vesicles from group B Neisseria meningitidis \u0394gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles","volume":"6","author":"Ferrari","year":"2006","journal-title":"Proteomics"},{"issue":"11","key":"10.1016\/j.vaccine.2009.04.071_bib27","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1002\/pmic.200500502","article-title":"Outer membrane vesicles of the VA-MENGOC-BC vaccine against serogroup B Neisseria meningitidis: analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry","volume":"6","author":"Uli","year":"2006","journal-title":"Proteomics"},{"issue":"11","key":"10.1016\/j.vaccine.2009.04.071_bib28","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1002\/pmic.200500821","article-title":"Proteomic analysis of meningococcal outer membrane vesicle vaccine prepared from group B strain NZ98\/254","volume":"6","author":"Vipond","year":"2006","journal-title":"Proteomics"},{"issue":"8","key":"10.1016\/j.vaccine.2009.04.071_bib29","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1128\/IAI.60.8.3156-3161.1992","article-title":"Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein","volume":"60","author":"van der Ley","year":"1992","journal-title":"Infect Immun"},{"issue":"13","key":"10.1016\/j.vaccine.2009.04.071_bib30","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1016\/j.vaccine.2006.09.025","article-title":"Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs","volume":"25","author":"van den Dobbelsteen","year":"2007","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2009.04.071_bib31","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/0264-410X(96)00020-5","article-title":"Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine","volume":"14","author":"Claassen","year":"1996","journal-title":"Vaccine"},{"issue":"20\u201321","key":"10.1016\/j.vaccine.2009.04.071_bib32","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1016\/S0264-410X(99)00044-4","article-title":"Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins","volume":"17","author":"Cartwright","year":"1999","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2009.04.071_bib33","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1073\/pnas.89.10.4633","article-title":"A vaccine carrier derived from Neisseria meningitidis with mitogenic activity for lymphocytes","volume":"89","author":"Liu","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"issue":"27","key":"10.1016\/j.vaccine.2009.04.071_bib34","doi-asserted-by":"crossref","first-page":"19266","DOI":"10.1016\/S0021-9258(18)41770-X","article-title":"Pore formation and mitogenicity in blood cells by the class 2 protein of Neisseria meningitidis","volume":"267","author":"Ulmer","year":"1992","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.vaccine.2009.04.071_bib35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0022-3476(05)81186-2","article-title":"Differences in the immunogenicity of three Haemophilus influenza type b conjugate vaccines in infants","volume":"121","author":"Granoff","year":"1992","journal-title":"J Pediatr"},{"issue":"8502","key":"10.1016\/j.vaccine.2009.04.071_bib36","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0140-6736(86)90001-2","article-title":"Immunogenicity in infants of Haemophilus influenza type b polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein","volume":"328","author":"Einhorn","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2009.04.071_bib37","unstructured":"Anonymus. Liquid PedvaxHIB. Product description. Merck & Co., Inc., West Point, PA, January 2001."},{"issue":"4","key":"10.1016\/j.vaccine.2009.04.071_bib38","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.4049\/jimmunol.172.4.2431","article-title":"Haemophilus influenza type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity","volume":"172","author":"Latz","year":"2004","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2009.04.071_bib39","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.vaccine.2006.03.092","article-title":"Improved immunogenicity of a H44\/76 group B outer membrane vesicle vaccine with over-expressed genome-derived Neisserial antigen 1870","volume":"25","author":"Koeberling","year":"2007","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2009.04.071_bib40","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1086\/589308","article-title":"Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with over-expressed fHbp and genetically-attenuated endotoxin","volume":"198","author":"Koeberling","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2009.04.071_bib41","series-title":"Abstract volume to the 16th international pathogenic Neisseria conference","first-page":"51","article-title":"Multivalent group B meningococcal vaccine based on native outer membrane vesicles (NOMV) has potential for providing safe, broadly protective immunity","author":"Zollinger","year":"2008"},{"key":"10.1016\/j.vaccine.2009.04.071_bib42","series-title":"Abstract volume to the 16th international pathogenic Neisseria conference","first-page":"273","article-title":"A phase 1 study of the safety and immunogenicity of an intramuscular group B meningococcal NOMV vaccine made from an lpxL2 and synX deleted strain","author":"Keiser","year":"2008"},{"issue":"1","key":"10.1016\/j.vaccine.2009.04.071_bib43","first-page":"S93","article-title":"Group B meningococcal OMV vaccine as a mucosal immunogen","volume":"76","author":"Dalseg","year":"1995","journal-title":"Clin Immunol Immunopathol"},{"issue":"4","key":"10.1016\/j.vaccine.2009.04.071_bib44","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1128\/IAI.66.4.1334-1341.1998","article-title":"Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans","volume":"66","author":"Haneberg","year":"1998","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2009.04.071_bib45","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1586\/14760584.1.2.227","article-title":"Can nonliving nasal vaccines be made to work?","volume":"1","author":"Haneberg","year":"2002","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2009.04.071_bib46","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1128\/IAI.70.2.702-707.2002","article-title":"Immunogenicity and safety testing of a group B Intranasal meningococcal native outer membrane vesicle vaccine","volume":"70","author":"Katial","year":"2002","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2009.04.071_bib47","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4049\/jimmunol.3.3.201","article-title":"The relation of the meningococcal activity of the blood to resistance to virulent meningococci","volume":"3","author":"Matsunami","year":"1918","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2009.04.071_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4049\/jimmunol.7.1.1","article-title":"A study of the virulence of meningococci for man and of human susceptibility to meningococci infection","volume":"7","author":"Heist","year":"1922","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2009.04.071_bib49","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"issue":"9","key":"10.1016\/j.vaccine.2009.04.071_bib50","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0264-410X(94)00037-N","article-title":"Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile","volume":"13","author":"Boslego","year":"1995","journal-title":"Vaccine"},{"issue":"8827","key":"10.1016\/j.vaccine.2009.04.071_bib51","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","article-title":"Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil","volume":"340","author":"de Moraes","year":"1992","journal-title":"Lancet"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2009.04.071_bib52","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","article-title":"Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease","volume":"21","author":"Holst","year":"2003","journal-title":"Vaccine"},{"issue":"17\u201318","key":"10.1016\/j.vaccine.2009.04.071_bib53","first-page":"2205","article-title":"From secondary prevention to primary prevention \u2013 a unique strategy that gives hope to a country ravaged by meningococcal disease","volume":"23","author":"O\u2019Hallahan","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.04.071_bib54","series-title":"Abstract volume to the 11th international pathogenic Neisseria conference","first-page":"169","article-title":"Development and evaluation of experimental meningococcal B: 4: P1.(7),4 outer membrane vesicle vaccine and evaluation in a mouse model","author":"Rosenqvist","year":"1998"},{"issue":"9","key":"10.1016\/j.vaccine.2009.04.071_bib55","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.vaccine.2005.09.043","article-title":"Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control","volume":"24","author":"Thornton","year":"2006","journal-title":"Vaccine"},{"issue":"17\u201318","key":"10.1016\/j.vaccine.2009.04.071_bib56","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","article-title":"MeNZB\u2122: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain","volume":"23","author":"Oster","year":"2005","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2009.04.071_bib57","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/aje\/kwm147","article-title":"A prospective study of the effectiveness of the New Zealand meningococcal B vaccine","volume":"166","author":"Kelly","year":"2007","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.vaccine.2009.04.071_bib58","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/ije\/dyn228","article-title":"Use of an observational study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years","volume":"38","author":"Galloway","year":"2009","journal-title":"Int J Epidemiol"},{"issue":"16","key":"10.1016\/j.vaccine.2009.04.071_bib59","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1016\/j.vaccine.2007.01.023","article-title":"Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand","volume":"25","author":"Oster","year":"2007","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2009.04.071_bib60","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1128\/IAI.63.12.4642-4652.1995","article-title":"Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine","volume":"63","author":"Rosenqvist","year":"1995","journal-title":"Infect Immun"},{"issue":"16","key":"10.1016\/j.vaccine.2009.04.071_bib61","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.281.16.1541","article-title":"Serogroup B meningococcal disease. New outbreaks, new strategies [editorial]","volume":"281","author":"Wenger","year":"1999","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.vaccine.2009.04.071_bib62","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1128\/IAI.64.7.2745-2751.1996","article-title":"Specificity of human bactericidal antibodies against PorA P1.7 16 induced with a hexavalent meningococcal outer membrane vesicle vaccine","volume":"64","author":"van der Voort","year":"1996","journal-title":"Infect Immun"},{"issue":"9","key":"10.1016\/j.vaccine.2009.04.071_bib63","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1128\/JCM.38.9.3323-3328.2000","article-title":"Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The active bacterial core surveillance team","volume":"38","author":"Tondella","year":"2000","journal-title":"J Clin Microbiol"},{"issue":"7","key":"10.1016\/j.vaccine.2009.04.071_bib64","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1128\/CVI.00047-06","article-title":"Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine","volume":"13","author":"Feiring","year":"2006","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2009.04.071_bib65","doi-asserted-by":"crossref","first-page":"16","DOI":"10.37757\/MR2007V9.N1.6","article-title":"Cuban meningococcal BC vaccine: experience and contributions from 20 years of application.","volume":"9","author":"Sotolongo Padron","year":"2007","journal-title":"MEDICC Rev"},{"key":"10.1016\/j.vaccine.2009.04.071_bib66","unstructured":"Martin D, Lopez L. The epidemiology of meningococcal disease in New Zealand in 2007. Report prepared for the Ministry of Health by the Institute of Environmental Science and Research Ltd.; 2008. Available at http:\/\/www.moh.govt.nz\/moh.nsf\/pagesmh\/8204\/$File\/meningo-annual-report-2007.pdf."},{"key":"10.1016\/j.vaccine.2009.04.071_bib67","series-title":"Abstract volume to the 16th international pathogenic Neisseria conference","first-page":"79","article-title":"Has MeNZB\u2122 controlled New Zealand's epidemic?","author":"Martin","year":"2008"},{"issue":"47","key":"10.1016\/j.vaccine.2009.04.071_bib68","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1016\/j.vaccine.2008.08.062","article-title":"MeNZB\u2122 vaccine and epidemic control: when do you stop vaccinating?","volume":"26","author":"Loring","year":"2008","journal-title":"Vaccine"},{"issue":"1270","key":"10.1016\/j.vaccine.2009.04.071_bib69","first-page":"110","article-title":"The role of MeNZB vaccination in controlling the New Zealand meningococcal epidemic","volume":"121","author":"Lennon","year":"2008","journal-title":"N Z Med J"},{"key":"10.1016\/j.vaccine.2009.04.071_bib70","series-title":"Abstract volume to the 16th international pathogenic Neisseria conference","first-page":"65","article-title":"Why stop MeNZB vaccination? Supporting evidence for withdrawal of epidemic strain outer membrane vesicle (OMV) vaccine in New Zealand","author":"Lennon","year":"2008"},{"issue":"1291","key":"10.1016\/j.vaccine.2009.04.071_bib71","first-page":"48","article-title":"Delivering a safe and effective strain specific vaccine to control an epidemic of group B meningococcal disease","volume":"122","author":"O\u2019Hallahan","year":"2009","journal-title":"N Z Med J"},{"issue":"16","key":"10.1016\/j.vaccine.2009.04.071_bib72","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1016\/j.vaccine.2007.01.022","article-title":"Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease","volume":"25","author":"N\u00f8kleby","year":"2007","journal-title":"Vaccine"},{"issue":"14","key":"10.1016\/j.vaccine.2009.04.071_bib73","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.vaccine.2005.12.059","article-title":"Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks","volume":"25","author":"Taha","year":"2007","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2009.04.071_bib74","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4161\/hv.3.5.4458","article-title":"Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand 2004\u20132006","volume":"3","author":"McNicholas","year":"2007","journal-title":"Hum Vaccines"},{"issue":"22","key":"10.1016\/j.vaccine.2009.04.071_bib75","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1016\/j.vaccine.2008.03.017","article-title":"The intensive vaccines monitoring programme (IVMP): an electronic system to monitor vaccine safety in New Zealand","volume":"26","author":"Tatley","year":"2008","journal-title":"Vaccine"},{"issue":"1263","key":"10.1016\/j.vaccine.2009.04.071_bib76","first-page":"1","article-title":"The risk of bronchiolitis hospitalization following administration of a group B meningococcal vaccine in New Zealand","volume":"120","author":"Stehr-Green","year":"2007","journal-title":"N Z Med J"},{"issue":"6","key":"10.1016\/j.vaccine.2009.04.071_bib77","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.vaccine.2007.12.001","article-title":"The risk of simple febrile seizures after immunization with a new group B meningococcal vaccine, New Zealand","volume":"26","author":"Stehr-Green","year":"2008","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2009.04.071_bib78","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/adc.2007.125195","article-title":"Henoch-Sch\u00f6nlein purpura and meningococcal B vaccination","volume":"94","author":"Sexton","year":"2009","journal-title":"Arch Dis Child"},{"issue":"5","key":"10.1016\/j.vaccine.2009.04.071_bib79","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1586\/14760584.6.5.863","article-title":"Neurological adverse events of immunization: experience with an aluminium adjuvanted meningococcal B outer membrane vesicle vaccine","volume":"6","author":"N\u00f8kleby","year":"2007","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2009.04.071_bib80","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.vaccine.2008.10.043","article-title":"Vaccination as teenagers against meningococcal disease and risk of chronic fatigue syndrome","volume":"27","author":"Magnus","year":"2009","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2009.04.071_bib81","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4161\/hv.4513","article-title":"Strategies for developing universal vaccines against serogroup B meningococcal disease","volume":"3","author":"Holst","year":"2007","journal-title":"Human Vaccines"},{"issue":"29","key":"10.1016\/j.vaccine.2009.04.071_bib82","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1016\/j.vaccine.2005.02.021","article-title":"Development and characterization of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis","volume":"23","author":"Norheim","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.04.071_bib83","series-title":"Fourteenth international pathogenic Neisseria conference","first-page":"181","article-title":"Prevention of serogroup A, C and W135 meningococcal disease in Africa with outer membrane vesicle vaccines","author":"Norheim","year":"2004"},{"key":"10.1016\/j.vaccine.2009.04.071_bib84","unstructured":"Miller E, Pollard AJ, Borrow R, Findlow J, Dawson T, Morant A, et al. Safety and immunogenicity of Novartis meningococcal serogroup B vaccine (MenB vaccine) after three doses administered in infancy. Abstract to ESPID, Graz, Austria; 2008."},{"issue":"S2","key":"10.1016\/j.vaccine.2009.04.071_bib85","first-page":"B41","article-title":"Meningococcal protein antigens and vaccines","volume":"27","author":"Feavers","year":"2009","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09006379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09006379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T07:08:32Z","timestamp":1684998512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09006379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":85,"alternative-id":["S0264410X09006379"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.04.071","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}